Latest Breaking News On - Teigland akay - Page 2 : comparemela.com

Hadean Ventures AS: Hadean Ventures announces oversubscribed final close of Hadean Capital II - a fund dedicated to investments in life science start-ups across Europe

Hadean Ventures Announces the 1st Closing of EUR 90m for its Second Fund

Hadean Ventures Announces the 1st Closing of EUR 90m for its Second Fund

Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round

Press release content from Business Wire. The AP news staff was not involved in its creation. Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round June 29, 2021 GMT OSLO, Norway (BUSINESS WIRE) Jun 29, 2021 Norway Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, announced today that the company has raised NOK 250 million in an oversubscribed pre-IPO financing round syndicated by existing investors Hadean Ventures, Geveran, RADFORSK Investeringsstiftelse, Sundt, Must Invest, Canica, MP Pensjon and Watrium. The net proceeds from the Private Placement are expected to ensure financing past end of 2023 for its lead product candidate Radspherin®, including financing of two clinical phase 2A studies (in ovarian cancer and colorectal cancer) as well as the advancement of the company’s proprietary targeted radiotherapy candidates. Oncoinvent has raised a total of NOK 535 million to date.

Norway Oncoinvent AS: Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round

Norway Oncoinvent AS: Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company to initiate the next phase of clinical development of its lead product candidate Radspherin Norway Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, announced today that the company has raised NOK 250 million in an oversubscribed pre-IPO financing round syndicated by existing investors Hadean Ventures, Geveran, RADFORSK Investeringsstiftelse, Sundt, Must Invest, Canica, MP Pensjon and Watrium. The net proceeds from the Private Placement are expected to ensure financing past end of 2023 for its lead product candidate Radspherin, including financing of two clinical phase 2A studies (in ovarian cancer and colorectal cancer) as well as the advancement of the company s proprietary targeted radiotherapy